![](https://news.europawire.eu/wp-content/uploads/2024/03/Novo-Nordisk-Acquires-Cardior-Pharmaceuticals-in-Billion-Euro-Deal-Pioneering-RNA-Therapies-for-Heart-Diseases-144x144.jpg)
(IN BRIEF) EQT Life Sciences proudly announces Novo Nordisk’s acquisition of Cardior Pharmaceuticals, valuing the biopharmaceutical company at up to EUR 1.025 billion. Based in Hannover, Germany, Cardior specializes in RNA-based therapeutics for cardiovascular diseases, focusing initially on heart failure. … Read the full press release